17-triol 7 17-ethynyl-5-androstene-3

01/01/2011 - "The pharmacology of HE3286 was characterized in preparation for clinical trials in type 2 diabetes mellitus and other diseases of inflammation. "
08/19/2014 - "HE3286 also attenuated the degree of inflammation, demyelination, and axonal loss in EAE optic nerves as compared to nerves from vehicle-treated EAE mice. "
05/01/2010 - "In primary murine macrophages, HE3286 attenuates LPS- and TNFalpha-stimulated inflammation. "
01/01/2012 - "HE3286 has shown efficacy in clinical studies in impaired glucose tolerance and type 2 diabetes, and in vivo models of types 1 and 2 diabetes, autoimmunity, and inflammation. "
08/19/2014 - "HE3286 suppresses inflammation, reduces demyelination and axonal loss, and promotes RGC survival during experimental optic neuritis. "

05/01/2010 - "In phase 2 clinical trials, HE3286 treatment led to an enhancement in insulin sensitivity in humans. "
01/01/2013 - "HE3286 decreased insulin resistance, increased the frequency of decreased day 84 HbA1c in metformin-treated subjects, and decreased day 112 HbA1c in treatment-naïve diabetics. "
04/01/2010 - "This effect appeared to be a consequence of reduced insulin resistance because HE3286 lowered blood insulin levels in db/db and ob/ob mice. "
05/01/2010 - "In line with reduced inflammation, HE3286 treatment normalized fasting and fed glucose levels, improved glucose tolerance, and enhanced skeletal muscle and liver insulin sensitivity, as assessed by hyperinsulinemic euglycemic clamp studies. "
01/01/2013 - "The anti-inflammatory insulin sensitizer, HE3286, was tested for its ability to decrease obesity-related inflammation-induced insulin resistance and metabolic dysregulation in diabetes. "

04/01/2010 - "Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis."
04/01/2010 - "HE3286 is currently in phase I/II clinical trials in rheumatoid arthritis and ulcerative colitis and these findings further strengthen the possibility that HE3286 may represent an effective anti-inflammatory agent useful for treating chronic inflammation with a more attractive safety profile than glucocorticoids or cyclooxygenase inhibitors."

01/01/2017 - "HE3286 is a synthetic sterol derivative that has shown therapeutic promise in models of inflammatory disease and neurodegenerative disease. "

08/19/2014 - "Results suggest that HE3286 is a potential novel treatment for optic neuritis."
08/19/2014 - "HE3286 reduces axonal loss and preserves retinal ganglion cell function in experimental optic neuritis."
08/19/2014 - "HE3286 suppresses inflammation, reduces demyelination and axonal loss, and promotes RGC survival during experimental optic neuritis. "
08/19/2014 - "HE3286's ability to suppress optic neuritis was examined in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. "